You are here

Article Text

Article menu

Download PDFPDF

SNIS 20th annual meeting electronic poster abstracts
E-169 Middle meningeal artery embolization with liquid embolic agents for chronic subdural hematoma: a systematic review and meta-analysis
Free
  1. A Mowla1,
  2. S Abdollahifard2,
  3. A Farrokhi2,
  4. O Yousefi2,
  5. A Valibeygi3,
  6. P Azami2
  1. 1Department of Neurological Surgery, University of Southern California, Los Angeles, CA, USA
  2. 2Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic Of
  3. 3Fasa University of Medical Sciences, Fasa, Iran, Islamic Republic Of

Abstract

Purpose In this systematic review and meta-analysis, we will assess the efficacy and safety of MMA embolization with liquid embolic agents and the outcomes of patients following this procedure.

Materials and Methods A review of the literature was carried out to identify the studies investigating the efficacy and safety of MMA embolization with liquid embolysate in Chronic Subdural Hematoma (cSDH) patients in PubMed, Scopus, Embase, and Web of science. The keywords liquid embolic agent, middle meningeal artery, cSDH, and embolization and their synonyms were used to build up the search strategy. R statistical software and random-effects model were used for analysis. Heterogeneity was reported as I2 and publication bias was calculated using Egger’s test.

Results Of the 628 articles retrieved, 14 studies were eligible to be included in this study. A total of data on 276 patients were analyzed. N-butyl cyanoacrylate and Onyx were the most commonly used embolizing agents. This study revealed a pooled mortality rate of 0%(CI:0.00-100%), recurrence and failure rate of 3%(CI:1-10%), reoperation rate of 4%(CI:2-12%), rate of size decrease of 94%(CI:79-98%), success rate of 100%(CI:76-100%) and adverse event rate of 1%(CI:0.00-4%).

Conclusions With low mortality, recurrence, reoperation, and adverse event rates and a remarkable decrease in the size of the hematoma, MMA embolization with liquid embolic might be considered a safe and effective treatment option in patients with previously failed surgical intervention and also as an alternative to the conventional treatments.

Disclosures A. Mowla: 2; C; to Cerenovus, Stryker, Wallaby Medical, RapidAI , BALT USA,LLC.. 3; C; to Cerenovus, Stryker, Wallaby Medical, RapidAI , BALT USA,LLC.. S. Abdollahifard: None. A. Farrokhi: None. O. Yousefi: None. A. Valibeygi: None. P. Azami: None.

https://doi.org/10.1136/jnis-2023-SNIS.268

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.